Dr. Christopher G. Azzoli
Director of Thoracic OncologyAffiliated Treatment Facilities
Doctor Overview
Dr. Christopher G. Azzoli is the Director of Thoracic Oncology at Brown University Health Cancer Institute in Providence, Rhode Island. He specializes in mesothelioma, lung cancer and thymoma. His research focuses on new drugs and blood tests for cancer patients. His father was a general surgeon, who inspired him to go into medicine. He followed his interest in cancer biology to focus on medical oncology. Dr. Azzoli is licensed to practice in Rhode Island and Massachusetts.
He is a Fellow of the American Society of Clinical Oncology (ASCO) and former Chairman of the ASCO Clinical Practice Guideline Committee. He has taught at Harvard Medical School, Memorial Sloan-Kettering Cancer Center and Massachusetts General Hospital Cancer Center.
Dr. Azzoli received his medical degree from Johns Hopkins University School of Medicine. He completed his residency in Internal Medicine at Johns Hopkins Hospital. He also did a fellowship in Hematology and Medical Oncology at Memorial Sloan-Kettering Cancer Center.
Doctor Fast Facts
Main Specialty: Thoracic Oncology
Other Interests & Specialties: Esophageal cancer, hematology, large-cell lung carcinoma, lung adenocarcinoma, lung cancer, medical oncology, mesothelioma, non-small cell lung cancer, pleuropulmonary blastoma, small cell lung cancer and squamous cell lung carcinoma.
Certifications, Awards & Accolades: American Board of Internal Medicine
Education & Experience:
- Medical Degree from Johns Hopkins University School of Medicine
- Residency in Internal Medicine at Johns Hopkins Hospital
- Fellowship in Hematology and Medical Oncology at Memorial Sloan-Kettering Cancer Center
Publications
Predictors of pneumonitis in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiation followed by consolidative durvalumab. Adv Radiat Oncol. 2023;8(2):101130.
Preclinical synergistic combination therapy of lurbinectedin with irinotecan and 5-fluorouracil in pancreatic cancer. Curr Oncol. 2023 Oct 31;30(11):9611–26.
Preclinical studies with ONC201/TIC10 and lurbinectedin as a novel combination therapy in small cell lung cancer (Sclc). Am J Cancer Res. 2022;12(2):729–43.
Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study. ESMO Open. 2022 Feb;7(1):100342.
